Prescribing of evidence-based diabetes pharmacotherapy in patients with metabolic dysfunction-associated steatohepatitis
Authors' conclusion
EBP prescriptions, especially pioglitazone, are low in patients with T2D and MASH, regardless of race/ethnicity. These data underscore the need for interventions to close the gap between current and evidence-based care.
Study context
- Population
- Patients with T2D and MASH (diagnosis codes, January 2019–January 2021) with ≥1 primary care or endocrinology encounter, Duke University Health System; mean age 59.7 (SD 12) years, 61.9% female
- Participants
- 847 patients
- Exposure
- EBP prescribing across racial/ethnic groups
- Blackn = 101
- Latino/a/xn = 39
- Outcome
- EBP: ≥1 prescription for pioglitazone and/or a GLP-1RA during the study period
Methodological detailssingle health system
- Single health system
Main finding
As reported in the abstract
EBP prescribed
Each group vs whiteAdjusted odds ratio (95% CI)P value
Latino/a/x
1.82(0.78–4.28)
Black
0.76(0.44–1.33)
P = 0.20- EBP prescribed, all patients
- 34.8% (n=295)
Observational data: associations, not effects.
Original publication
Prescribing of evidence-based diabetes pharmacotherapy in patients with metabolic dysfunction-associated steatohepatitis. BMJ Open Diabetes Res Care. Published 29 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →